Genocea Biosciences, Inc. (NASDAQ:GNCA) has received a consensus rating of “Buy” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $4.87.

Several equities analysts have recently issued reports on the company. Cowen and Company reiterated an “outperform” rating and issued a $40.00 price target on shares of Genocea Biosciences in a research note on Tuesday, July 25th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $18.00 price target (up previously from $17.00) on shares of Genocea Biosciences in a research note on Tuesday, July 25th. ValuEngine upgraded Genocea Biosciences from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Needham & Company LLC lowered Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Finally, Stifel Nicolaus lowered Genocea Biosciences from a “buy” rating to a “hold” rating and decreased their price target for the company from $15.00 to $2.50 in a research note on Monday, September 25th.

TRADEMARK VIOLATION WARNING: “Genocea Biosciences, Inc. (GNCA) Given Consensus Rating of “Buy” by Brokerages” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/13/genocea-biosciences-inc-gnca-given-consensus-rating-of-buy-by-brokerages.html.

Genocea Biosciences (NASDAQ:GNCA) opened at $1.16 on Monday. Genocea Biosciences has a 52 week low of $1.03 and a 52 week high of $7.29. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.55 and a current ratio of 1.55.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.08). During the same quarter in the prior year, the company posted ($0.45) earnings per share. analysts anticipate that Genocea Biosciences will post -1.91 EPS for the current year.

A number of hedge funds have recently modified their holdings of the stock. Northpointe Capital LLC grew its position in Genocea Biosciences by 9.6% during the 2nd quarter. Northpointe Capital LLC now owns 1,336,062 shares of the biotechnology company’s stock worth $6,974,000 after acquiring an additional 117,374 shares during the last quarter. Vanguard Group Inc. grew its position in Genocea Biosciences by 13.9% during the 2nd quarter. Vanguard Group Inc. now owns 856,762 shares of the biotechnology company’s stock worth $4,472,000 after acquiring an additional 104,790 shares during the last quarter. State Street Corp grew its position in Genocea Biosciences by 1,595.2% during the 2nd quarter. State Street Corp now owns 366,172 shares of the biotechnology company’s stock worth $1,912,000 after acquiring an additional 344,572 shares during the last quarter. Northern Trust Corp grew its position in Genocea Biosciences by 642.9% during the 2nd quarter. Northern Trust Corp now owns 306,597 shares of the biotechnology company’s stock worth $1,601,000 after acquiring an additional 265,328 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Genocea Biosciences by 4.7% during the 1st quarter. Geode Capital Management LLC now owns 148,370 shares of the biotechnology company’s stock worth $903,000 after acquiring an additional 6,708 shares during the last quarter. Institutional investors and hedge funds own 56.73% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Analyst Recommendations for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.